Mutual Funds that own Orexo AB
ATP Group Portfolio
2,040,633
5.91%
0
0.01%
12/31/2017
Lupus alpha Fonds - Micro Champions
180,000
0.52%
180,000
1.64%
12/31/2017
Arbor Invest - Vermoegensverwaltungsfonds
150,000
0.43%
150,000
1.42%
12/31/2017
HRK Invest - Leopoldfonds
120,000
0.35%
120,000
1.71%
06/30/2018
USAA International Fund
107,910
0.31%
0
0.01%
06/30/2018
SEB Sverige Indexfond
106,711
0.31%
0
0.03%
12/31/2017
SEI Global Master Fund Plc - Pan European Small Cap Equity
84,115
0.24%
0
0.12%
06/30/2018
AcomeA Europa
78,901
0.23%
-1,099
0.32%
10/31/2017
DFA Continental Small Company Series
48,880
0.14%
13,918
0%
01/31/2018
SEI Global Master Fund Plc - European (ex-UK) Equity Fund
41,006
0.12%
-1
0.04%
06/30/2018
| Address |
Rapsgatan 7e
Uppsala UP 751 05
Sweden
|
|
Employees
|
- |
| Website |
http://www.orexo.com |
| Updated |
07/08/2019 |
| Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. Its focuses on the treatment of opioid dependence. Its pipeline comprises of Zubsolv, Abstral, Edluar, Zubsolv, OX51, OX-MP1, and OX382. |
